TEMPUS

Comprehensive Profiles Requisition 2026.07.21

p: 800.739.4137 | f: 800.893.0276 | e: support@tempus.com
If any information is incomplete or missing, testing may be delayed.

Associated Study	Study ID

ORDERING PHYSICIAN INFORMATION

Ordering Physician (full legal name)				NPI #
Facility Name	Tempus Account #	Email (required for report delivery)		Fax
Facility Address (Street, Unit)	City	State	Postal Code	Country

Additional person to be copied			**Form completed by**		
Name	Email/Fax	Facility Name	Name	Email/Fax	Facility Name

PATIENT INFORMATION

Last Name		MI	First Name	
DOB (MM/DD/YYYY)	Medical Record #	Biological Sex ☐ F ☐ M ☐ Unknown	Email	Phone

Address (Street, Unit)	City	State	Postal Code	Country

BILLING INFORMATION

Primary insurance plan name	Policy #	Group#	Policy Holder Name	Policy Holder DOB

Patient relationship to policy holder: ☐ Self ☐ Spouse ☐ Child ☐ Other:

Bill Type: ☐ Insurance ☐ Hospital/Institution ☐ Self pay/International

CURRENT CANCER DIAGNOSIS

☐ Biliary	☐ Colorectal	☐ Heme	☐ Pancreatic
☐ Bladder	☐ Endometrial	☐ Hepatocellular	☐ Prostate
☐ Breast	☐ Esophageal	☐ Melanoma	☐ Renal
☐ Cancer of Unknown Primary	☐ Gastric	☐ NSCLC	☐ Sarcoma
☐ Cervical	☐ Head and Neck	☐ Ovarian	☐ Thyroid
☐ Central Nervous System			☐ Other

Disease Status (select all that apply):
☐ Metastatic, refractory, relapsed, or recurrent
☐ Other

Stage:

Date of curative intent surgery (if any):

Current treatment(s) include:
☐ Chemotherapy ☐ Radiation ☐ No Evidence of Disease/none
☐ Immunotherapy/ICI, drug name:

Primary ICD-10 Codes (C, D, & Z codes):

Has the patient had any type of transplant? ☐ No ☐ Yes; Type:

TESTING OPTIONS

When ordering xT, Tempus will run CDx if requirements are met, and LDT otherwise.

Comprehensive Therapy Selection [1]

☐ xT (DNA), xR (RNA), and tailored testing add-ons by current cancer diagnosis

LIQUID BIOPSY ADD-ONS *(select only one):*

☐ Add xF+ concurrently
☐ Reflex to xF [2]

HEREDITARY ADD-ONS:

☐ Add CancerNext-*Expanded*® [3]
↳ ☐ +RNAinsight®

Comprehensive MRD & Disease Monitoring

☐ xM (NeXT Personal® Dx)
Tissue-informed MRD and disease monitoring test [3]

☐ xM for MRD (Minimal Residual Disease)
Tissue-free MRD test for resectable CRC

Testing is for 12 months unless total number of draws is entered. Please enter total number of draws: _____

Recurring draw schedule:

☐ every 4 weeks [4] ☐ every 3 months ☐ 1 time
☐ every 6 weeks [4] ☐ every 6 months

Individual Test Options

SOLID TUMOR & HEME

Tumor + normal:	☐ xT + xR (DNA + RNA) ↳ ☐ Reflex to xF [2]	☐ xT ↳ ☐ Reflex to xF [2]	
Tumor only:	☐ xT + xR (DNA + RNA)	☐ xT (DNA)	☐ xR (RNA)
Heme	☐ xT + xR (DNA + RNA)	☐ xT (DNA)	☐ xR (RNA)

LIQUID BIOPSY

☐ xF+
☐ xF

HEREDITARY

☐ CancerNext-*Expanded*® [3]
↳ ☐ Add +RNAinsight®
☐ CancerNext® [3]
↳ ☐ Add +RNAinsight®

☐ BRCAplus® [3]
↳ Reason for STAT test:
☐ Surgery ☐ Pregnancy
☐ Other;
↳ Date results needed:

Add-on Tests

TISSUE-BASED TESTS

☐ PD-L1 (22C3)	☐ HER2 + FISH Reflex [3]	☐ c-MET [3]
☐ PD-L1 (SP142)	☐ MMR	☐ MGMT [3]
☐ PD-L1 (SP263)	☐ FOLR1 [3]	☐ 1p/19q [3]
☐ PD-L1 (28-8)	☐ CLDN18 [3]	☐ ArteraAI Prostate Test (mHSPC) [3]

ALGORITHMIC TESTS [1]

☐ IPS
☐ HRD
☐ TO (RNA)
☐ PurIST℠ (RNA, Panc)

PHARMACOGENOMIC TESTS

☐ RightMed Comprehensive (27 genes)
OR ☐ UGT1A1 ☐ DPYD

1 *Tempus uses the diagnosis information you provide to determine tests ordered by current cancer diagnosis. See tempus.com/testing-resources/ for tests ordered by current cancer diagnosis.*
2 *Reflex to xF in the event xT results in QNS or no actionable variants.*
3 *Powered by a Tempus partner lab.*
4 *Available for NeXT Personal® Dx only.*

Tempus will rerun therapies and notify you when there are updates for the following assays: xT, xT CDx, xF, xF+, and xR. You can opt out of receiving these updates by contacting your customer support representative.

SPECIMEN RETRIEVAL

See Tempus' specimen guidelines for collection instructions and further details.

☐ **FFPE Tissue** / ☐ **Bone Marrow Aspirate** *Submitting pathologist will choose FFPE Tissue if specimen details are not provided.*

Pathology Lab (Name, City)		Specimen Collection Facility	Patient status at time of specimen collection:
Case Number	Block #	Date of Collection / Biopsy to be scheduled for	☐ Office/Non-Hospital ☐ Hospital Outpatient ☐ Hospital Inpatient → ☐ Not yet discharged ***OR*** Discharge date:

☐ **Blood** / ☐ **Saliva** / ☐ **Other**

☐ Mobile phlebotomy
☐ Send saliva kit to patient
☐ Sample previously submitted
☐ Clinic first draw, mobile phlebotomy subsequent draws (MRD Only)

Date of Collection: Specimen Collection Facility:

Patient status at time of specimen collection:
☐ Office/Non-Hospital
☐ Hospital Outpatient
☐ Hospital Inpatient → ☐ Not yet discharged ***OR*** Discharge date:

PHYSICIAN SIGNATURE & CONSENT

By signing and/or submitting the order, I certify that (1) the patient has received an explanation of the purpose, risks, and benefits of the ordered test(s); (2) the ordered test(s) are medically necessary and will inform the patient's treatment plan; (3) unless otherwise set forth on this form, the patient has recurrent, relapsed, refractory, metastatic, or advanced stage III or IV cancer; and (4) the patient has provided informed consent that meets the requirements of applicable law for Tempus or its reference lab to: (a) collect and use the patient's samples (including genetic material) and health information and perform the ordered test(s); (b) obtain, receive, and release health information (including test results) as necessary for reimbursement or the processing of insurance claims; (c) retain and use samples and health information for an indefinite period of time in accordance with applicable law; and (d) de-identify such samples and information and use and share the resulting de-identified samples and information in accordance with applicable law.

In addition, I certify that if xT and xF/xF+ are ordered within 30 days of one another, the order is medically necessary because guidelines support the use of testing, turnaround time for tissue result may delay a treatment decision, the tissue is at risk to fail (e.g. small tissue, archived tissue) and I may not have a timely result to make a treatment decision; and/or genomic heterogeneity may cause available tissue to not be completely representative, and I want to make sure I have a complete mutation profile.

Included Attachments: ☐ Copy of patient's progress notes and/or medical records ☐ Copy of recent pathology report ☐ Copy of insurance card

Ordering Physician Signature: Printed Name (full legal name): Today's Date (MM/DD/YYYY):

Phone: 800.739.4137 | Fax: 800.893.0276 | support@tempus.com
600 West Chicago Avenue Suite 510, Chicago, IL 60654 | **tempus.com**

Test Name	Description	Acceptable Specimen(s)	Kit Type
xT CDx	FDA-approved 648-gene DNA sequencing test.	FFPE tissue, normal sample must be blood or saliva	Tempus Tissue, Blood, Saliva
xT LDT	648-gene DNA sequencing test.	FFPE tissue, or blood (EDTA), or bone marrow aspirate (EDTA)	Tempus Tissue, Heme
xR	Whole transcriptome RNA sequencing test.	FFPE tissue, or blood (EDTA), or bone marrow aspirate (EDTA)	Tempus Tissue, Heme
xF	105-gene liquid biopsy tests for solid tumors.	Blood (Streck)	Tempus Blood
xF+	523-gene liquid biopsy tests for solid tumors.	Blood (Streck)	Tempus Blood
CancerNext®	Guideline-based germline panel for hereditary cancers with established clinical management recommendations.	Blood (EDTA) or saliva	Hereditary Blood (DNA), Hereditary Saliva (DNA)
CancerNext-*Expanded*®	Expanded germline panel providing broader coverage for hereditary cancer predisposition genes.	Blood (EDTA) or saliva	Hereditary Blood (DNA), Hereditary Saliva (DNA)
+RNAinsight®	Supplemental germline RNA sequencing, powered by Ambry Genetics. Not available with BRCAplus® or STAT orders.	Blood (PAXgene®)	Hereditary Blood (DNA+RNA)
BRCAplus®	Guideline-based STAT panel for hereditary breast cancer.	Blood (EDTA) or saliva	Hereditary Blood (DNA), Hereditary Saliva (DNA)
xM (NeXT Personal® Dx)	Tissue-informed test for monitoring cancer, test by Personalis.	Initial test requires: FFPE tissue, blood (EDTA), and blood (Streck). Subsequent tests require: blood (Streck).	Tempus Tissue, xM (NeXT Personal® Dx) Blood
xM	Tissue-free MRD for resectable CRC.	Blood (Streck)	Tempus xM MRD Blood

xT CDx logistical details: *For details on test requirements and reflex protocols, visit* tempus.com/testing-resources.

The following fields are for Pharmacogenomic orders ONLY. Disregard if not ordering PGx.

ETHNICITY *(Select one option.)*

- ☐ White or Caucasian
- ☐ Black/Sub-Saharan African/African American
- ☐ American Indian or Alaska Native
- ☐ Ashkenazi Jewish
- ☐ Sephardi Jewish
- ☐ East Asian
- ☐ Central/South Asian
- ☐ Near/Middle Eastern
- ☐ Hispanic or Latino
- ☐ Native Hawaiian or Other Pacific Islander
- ☐ First Nation/Inuit/Métis

TREATMENTS CURRENTLY PRESCRIBED OR UNDER CONSIDERATION *(Select all that apply.)*

HEMATOLOGY/ONCOLOGY

- ☐ Belinostat (Beleodaq®)
- ☐ Capecitabine (Xeloda®)
- ☐ Fluorouracil
- ☐ Gefitinib (Iressa®)
- ☐ Irinotecan (Camptosar®)
- ☐ Mercaptopurine (Purixan®)
- ☐ Nilotinib (Tasigna®)
- ☐ Pazopanib (Votrient®)
- ☐ Thioguanine (Tabloid®)
- ☐ Tamoxifen
- ☐ Sacituzumab Govitecan-hziy (Trodelvy®)
- ☐ Other drug

The following fields are for CancerNext® or CancerNext-*Expanded*® orders ONLY. Disregard if not testing for hereditary cancers.

RELEVANT CLINICAL HISTORY *(Previous cancer diagnosis, GI polyps, etc.)*

FAMILY HISTORY

☐ **None/No known family history** ☐ **Unknown** ☐ **Adopted**

Relationship to patient	Maternal	Paternal	Age at diagnosis	Details of relevant history
	☐	☐		
	☐	☐		
	☐	☐		
	☐	☐		

ANCESTRY

- ☐ White/Caucasian
- ☐ Hispanic
- ☐ Black/African American
- ☐ Native American
- ☐ East Asian
- ☐ South Asian
- ☐ Middle Eastern
- ☐ Ashkenazi Jewish
- ☐ Other:

BONE MARROW TRANSPLANT

Personal history of allogeneic bone marrow or peripheral stem cell transplant: ☐ Yes ☐ No

Note: Using a blood or saliva sample is not appropriate for patients who have undergone an allogeneic bone marrow or peripheral stem cell transplant.

PRIOR PERSONAL OR FAMILY HISTORY OF GENETIC TESTING

**For comments related to a prior test result, include the gene and variant (c. and/or p.) AND a test order ID or a copy of the result (required if external lab).*

☐ No personal or family history of molecular and/or genetic testing.

Relationship to patient: ☐ Self ☐ Family member:

☐ Germline testing *

Test performed: Results:

Microsatellite instability analysis:
- ☐ Stable (MSS)
- ☐ Unstable/High (MSI-High)
- ☐ Unstable/Low (MSI-Low)

☐ Somatic/tumor testing *

Test performed: Results:

☐ Immunohistochemical staining

Proteins present: Proteins absent:

Phone: 800.739.4137 | Fax: 800.893.0276 | support@tempus.com
600 West Chicago Avenue Suite 510, Chicago, IL 60654 | **tempus.com**